U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088588) titled 'Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors' on July 18.
Brief Summary: This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Cancer
Metastatic Solid Tumor
Ovarian Cancer
Breast Cancer
BRCA Mutation
HRR Deficiency
Intervention:
DRUG: SYN608
Patients will orally receive SYN608
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., L...